The company is expanding their capacities aggressively. And looking at the forecast, it looks like there will be a lot more capex planned in the years to come. This is where most of the outflow is over the past couple of years:
On the operations side - receivables have been growing year over year. This often reflects as lower CFO as profits are not converting to cash on the company’s books immediately. This is also what is causing the debtor days to increase. In my opinion - the company seems to be focusing on grabbing market share, and is compromising on the quality of the deals (lenient payment terms) in order to do so. Hopefully as the company’s client base matures, the receivables on the balance sheet also improves with time.
And regarding the lack of institutional holding, I often like to quote Peter Lynch’s ‘One up on wall street’
“If you find a stock with little or no institutional ownership, you’ve found a potential winner. Find a company that no analyst has ever visited, or that no analyst would admit to knowing about, and you’ve got a double winner. When I talk to a company that tells me the last analyst showed up three years ago, I can hardly contain my enthusiasm.”
His theory is to get in before the institutions. If institutional ownership is already high, there’s not much room to grow. Just some food for thought.
Tuesday, 4th February 2025: Sigachi Industries Limited, a leading player in Pharmaceutical
Industry provided an update regarding its efficient resource deployment and enhancing
R&D Productivity by establishing Research and Development facility in Hyderabad, India.
This strategic initiative involves an investment of up to USD 1 Million and is set to
commence immediately, reinforcing Sigachi’s commitment to innovation and long-term
growth and efficiency
Extensive experience in the excipients industry, scaling up by offering value added products & flexibility to differentiate and gain share
a) Outperformance: Global MCC industry growth rate ~8% vs. Sigachi’s MCC growth rate ~15-20%
b) Launching CCS – a complementary product with higher value and margin accretion
Expanding its presence in the pharma value chain: Acquired 80% stake in Trimax Bio Sciences to expand into API
Huge headroom for growth in asset light Operations & Management business
Strategic Alliance to Drive Expansion-JVs
Ability to maintain margins and expand further
– Key Risk to Monitor:
Scale up of API segment & timely receipt of CEP approvals
Set up of CCS facility
Number of working capital days/days of receivables
Thursday, 17th April 2025: Sigachi Industries Limited, India’s leading player in
pharmaceutical excipients and specialty ingredients, has received Environmental
Clearance (EC) from the State Environment Impact Assessment Authority (SEIAA), Gujarat for its upcoming Greenfield manufacturing facility at Dahej SEZ, Bharuch, Gujarat. This paves the way for one of Sigachi’s most significant capacity expansions to date, reinforcing the company’s vision to become a global manufacturing powerhouse for excipients, nutraceuticals, and high-value functional ingredients.
Environmental Clearance received on April 16, 2025, with site development and execution
set to begin immediately.
Strategic Highlights:
• Positioned in Dahej SEZ to drive export growth, operational flexibility, and compliance
readiness for regulated markets
• Installed Production Capacity of 3,120 MT/month — across categories including
Cellulose and Starch based specialized Excipients, among others.
• Product portfolio tailored to pharmaceutical, nutraceutical, and food-grade applications
— tapping into high-margin, fast-growing segments in regulated and semi-regulated
markets.
Monday, 28th April 2025: Sigachi MENA FZCO, a wholly owned subsidiary of Sigachi Industries Limited, has signed a Memorandum of Understanding (MoU) with Respilon, an innovation-driven nanofiber R&D company headquartered in the Czech Republic.
This partnership marks a significant milestone in Sigachi’s strategy to expand into advanced drug delivery technologies.
The MoU was signed between Mr. Lijo Chacko, Managing Director of Sigachi MENA FZCO,
and Mr. Roman Zima, Chief Business Officer of Respilon Group s.r.o, during a formal
ceremony on April 24, 2025.
Strategic Highlights of the MoU:
Sigachi and Respilon will collaborate to develop, manufacture, and commercialize drug
delivery solutions based on Respilon’s proprietary NUENEX® nanofiber technology.
Focus on the development of Invisible Patch and Powder-based pharmaceutical delivery
formats.
The collaboration includes developing commercialization strategies for relevant APIs
and formulations, leveraging nanofiber encapsulation technology.
They expect a stable price increase in MCC price/kg of around 4-5% a year
They can increase efficiency of current production lines to 25k metric tonnes of MCC (from 21k). 25% growth from current capacity itself can be achieved this year.
O&M business
Added Adani Solar as a client
Evolved into a stable revenue stream
Target: 75-80Cr in FY’26
Targeting Middle East customers
CCS plant
Environment clearance received. 18 months to commission (October 2026)
Expecting 35% utilisation in the first year
CCS market is 1/8th of cellulose market. So existing MCC customer base themselves will end up being CCS customers.
MCC binds the tablet while CCS breaks the tablet down in the body.
90Cr Capex. 55Cr might be raised via debt (not yet finalised). Remaining will be from IPO funds secured.
Asset turns of 3-4X expected.
2 years to reach 90Cr turnover (optimal capacity utilization)
API molecules
In August’23, Trimax was acquired. In FY’24 this business was bleeding due to low margins. They let go of a lot of these segments and are now focusing on high margin products. Hence in FY’25 topline might have been lesser but this business was at-least EBIDTA positive.
29Cr sales this year, 20% EBIDTA from this segment
Capacity expansion of 150KL has not yet commenced.
4 CEPs filed, 1 approval received. 5 more CEPs to be filed this calendar year.
Other points:
Not much clarity on the US Tariffs as of yet.
Revenue growth outlook remains the same at 25%+ for the next 2-3 years
Margins are stable and will increase towards 25% with the product mix changing to higher value added products
Receivables issue from foreign customers is resolved. Maybe 10% remaining which they will also receive very soon.
Contribution to revenue: Top 5 customers - 43%, Top 10 customers - 60%
Friday, 13th June 2025: Sigachi Industries Limited, a leading player in pharmaceutical excipients and active ingredients, has received the Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh for its upcoming Bulk Drugs, Drug Intermediates, and Specialty Chemicals facility at Orvakal, Kurnool District.
This strategic project is proposed over 25.09 acres at Plot No. A-10, Guttapadu-Orvakal
Node. The facility falls under Category B1, aligned with Schedule 5(f) of the EIA Notification,
2006, applicable to the Synthetic Organic Chemicals sector.
With the Terms of Reference now in place, the Environmental Clearance (EC) process is set
to commence from 15th July 2025, followed by project development activities beginning
from 1st August 2025.
The project will be instrumental in:
Enhancing the company’s API manufacturing capacity and global reach.
Supporting pipeline expansion for regulated and semi-regulated markets.
Establishing a strategically located facility with export potential.
Contributing to “Make in India” through world-class infrastructure and sustainable
practices.
Shares of Sigachi Industries plunged 14.8% to Rs 47 on Monday after a massive explosion and fire at its pharmaceutical plant in Telangana’s Pashamylaram industrial area. A chemical reactor blast led to at least 8 deaths and over 20 injuries, collapsing one building and sparking investor fears about operational disruptions and regulatory consequences amid the unfolding tragedy.
The death toll has unfortunately crossed 40 and things are going from bad to worse.
One of the victim’s family has also registered a culpible homicide complaint against the company for ignoring repeated warnings about unsafe and outdated machinery. The more we read about it, the more it looks like Sigachi’s ignorance was the root cause. The Telangana govt. will not take this lightly.
A meeting was held with the management of Sigachi Industries to discuss the company’s performance, strategic initiatives, and future outlook. Key insights from the discussion are summarized below.
Key Highlights
Industry Growth and Divisions: The pharmaceutical industry is growing at 8-9% annually. The oral dosage division is expanding faster than the injectables division.
Product Composition: Approximately 70-80% of the drug consists of inactive ingredients. The tablet value is primarily driven by active components. Whereas excipients are only 10% of tablet value. The low cost is a reason for customer stickiness.
Core Products: MCC (Microcrystalline Cellulose) is the prime product. Compaction is a key functionality for tablet strength. APIs may need coating for stability.
Raw Materials: Raw materials are purified pulp, fully imported. Annual contracts are in place with major suppliers.
Competition: The largest manufacturer has 100,000 MT. Roquette, the largest leased-out entity from France, and JRS Pharma, the second largest based in Germany, are key players. JRS has a JV with Gujarat Microwax based out of Ahmedabad. They have a capacity of 18000MT.
CCS: Just as MCC helps in compaction, CCS helps in disintegration. Company is setting up a new plant of 1800 MTPA.
Capex: A new SEZ unit on a 20-acre land parcel is planned, where the CCS plant of 1800 MTPA will be set up. The plant is expected to get commissioned in October 2026. They will also plan a capex of 12000 MTPA of MCC, though timing remains unconfirmed. The CCS unit is 6 months behind schedule. 90-100 crores will be spent for the CCS plant and a similar amount will be spent to set up the MCC plant.
Initially the CCS plant will give an asset turn of 1x and can go upto 2.5x to 3x as new capabilities are added. Cost of brownfield capex is ~20% of greenfield capex.
API: Company did a sales of Rs.50 crores in last year as they were aggressively chasing sales; but did not make any profits. Last year did a sale of Rs. 29 crores but were PAT positive. Will target sales of Rs.70 crores from API division. Can expect a margin of 18-19% from APIs. The maximum sales from this facility can be Rs. 120-130 crores.
There is a very negative sentiment around the company. Further there are statements like these which may cause further negative impact going forward:
My father and others had raised concerns multiple times about the ageing equipment. They warned the management that continued use of the outdated machinery could result in disaster — but no one listened,” Yashwanth was quoted by ToI as saying.
In the aftermath, Telangana Chief Minister A Revanth Reddy visited the blast site along with Ministers Sridhar Babu, Damodara Raja Narasimha, G Vivek, and P Srinivasa Reddy.
Expressing sharp disapproval of the company’s handling of the crisis, the Chief Minister reprimanded Sigachi’s top management for staying absent during the critical hours after the tragedy, reported PTI.
“Major accident has taken place. He (senior management) has to come. He has to visit the deceased person’s families. You can not avoid the situation. He has to come. Ask him to come,” the CM told a company representative, demanding a detailed report on the incident, including the firm’s safety record and previous accidents, if any.
Also there is no upside even after factoring current capex plans. Further after reading, it is quite evident the MCC business is a cash cow, but the management is unable to find adjacent businesses to deploy cash at higher or similar ROCEs. It’s a sell on rise. If available at ~Rs.20; which it can be as numbers would be a challenge this year due to fire, then we can buy the stock.
What happened sounds absolutely horrible, hopefully this sets an example to take health & safety more serious in the future. My thoughts are with the families that lost their loved ones in an accident that could have been prevented by proper maintenance.
Does anyone have any insights on Sigachi’s API manufacturing capabilities and whether this is affected by the factory explosion? On their website it says they manufacture API’s such as Pregabalin, Ritonavir, Metformin, Propafenone etc… but I cannot find any export of these on PharmaChem Investor (tracking platform I use). Would anyone be able to provide any insights on this?
I am trying to find a reasonable estimation for 2 open questions:
While what we are listening/reading in the aftermath of the incident not good, will it have any impact on its O&M division, which is fast growing (albeit at a much lower base) with higher margin profile? If yes, it takes away a great optionality for the firm. If anyone has done scuttlebutt on this, pls share.
Considering the scale of the incident, can they turnaround things in just 90 days and resume ops at Hyd plant? If it needs longer timeline, it is going to be huge blow for FY26 performance considering this facility accounts for ~30% of the MCC capacity.
Disclaimer: made investments in last 30 days. May add more in case of precipitous fall in price despite satisfactory remediation of the ongoing issue
How is MCC the same as Metformin (3-(diaminomethylidene)-1,1-dimethylguanidine)? As far as I am aware, Metformin API is not based upon MCC, and MCC is only used to formulate tablets. Are you saying their main revenue source is formulated Metformin tablets?
